9ESA

Aurora-C with SER mutation in complex with INCENP peptide

これはPDB形式変換不可エントリーです。

9ESA の概要

• エントリーDOI: 10.2210/pdb9esa/pdb
• 分子名称: Aurora kinase C, Inner centromere protein, 1,2-ETHANEDIOL, ... (4 entities in total)
• 機能のキーワード: surface entropy reduction, ser, kinase, transferase, transcription
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 83754.61

構造登録者

Hillig, R.C. (登録日: 2024-03-26, 公開日: 2024-09-11, 最終更新日: 2024-09-25)

主引用文献

Schaefer, M.,Putter, V.,Hilpmann, A.,Egner, U.,Holton, S.J.,Hillig, R.C.
Surface-mutagenesis strategies to enable structural biology crystallization platforms.
Acta Crystallogr D Struct Biol, 80:661-674, 2024

PubMed Abstract: A key prerequisite for the successful application of protein crystallography in drug discovery is to establish a robust crystallization system for a new drug-target protein fast enough to deliver crystal structures when the first inhibitors have been identified in the hit-finding campaign or, at the latest, in the subsequent hit-to-lead process. The first crucial step towards generating well folded proteins with a high likelihood of crystallizing is the identification of suitable truncation variants of the target protein. In some cases an optimal length variant alone is not sufficient to support crystallization and additional surface mutations need to be introduced to obtain suitable crystals. In this contribution, four case studies are presented in which rationally designed surface modifications were key to establishing crystallization conditions for the target proteins (the protein kinases Aurora-C, IRAK4 and BUB1, and the KRAS-SOS1 complex). The design process which led to well diffracting crystals is described and the crystal packing is analysed to understand retrospectively how the specific surface mutations promoted successful crystallization. The presented design approaches are routinely used in our team to support the establishment of robust crystallization systems which enable structure-guided inhibitor optimization for hit-to-lead and lead-optimization projects in pharmaceutical research.

PubMed: 39207897
DOI: 10.1107/S2059798324007939

実験手法

X-RAY DIFFRACTION (2.8 Å)